[Ala1,3,12,Gln10,Arg11,Trp14]Pth(1-14)/[Ala18,22, Lys26]Pthrp(15-36)Cooh

2 trials 1 recruiting Orphan designation

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

0 Completed trials

2 Sponsors

10 Countries

Phase III

Phase III: 2

Indications tested

Hypoparathyroidism 2

Sponsors using this IMP

Alexion Pharmaceuticals Inc. 1 Amolyt Pharma 1

All trials

2 total

Evaluation of the efficacy and safety of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO) Not authorised

2022-503126-12-00 Phase III 1 country Amolyt Pharma
Evaluation of the efficacy and safety of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO) Recruiting

2022-503126-12-01 Phase III 10 countries Alexion Pharmaceuticals Inc.

Showing 1–2 of 2 trials

← All drugs A–Z